The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

Background: This study investigated the humoral responses to SARS-CoV-2 in hemodialysis (HD) patients. The clearance of molecules in the blood during hemodialysis is influenced by factors such as filter pore size, flow rate, operating pressure, and treatment duration. Chronic kidney disease patients...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ji Young Park, Seong-Ho Choi, Yong Kwan Lim, Jungho Shin, Soie Kwon, Haein Kim, Jin-Won Chung
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Series:	Vaccines
Subjects:	antibodies neutralizing renal dialysis SARS-CoV-2 vaccination
Online Access:	https://www.mdpi.com/2076-393X/13/2/170
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography
by: Jianqiang Ma, et al.
Published: (2025-02-01)

A Hidden Guardian: The Stability and Spectrum of Antibody-Dependent Cell-Mediated Cytotoxicity in COVID-19 Response in Chinese Adults
by: Jinge Cao, et al.
Published: (2025-02-01)

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
by: Liubov I. Kozlovskaya, et al.
Published: (2021-01-01)

Viral and immune profiles during the first wave of SARS-CoV-2 infection in hospitalized patients in Sardinia, Italy
by: Giulietta Venturi, et al.
Published: (2025-02-01)

Serological Correlate of Protection<italic/> Established by Neutralizing Antibodies Differs Among Dialysis Patients with SARS-CoV-2 Variants of Concern
by: Guy Rostoker, et al.
Published: (2025-05-01)

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
by: Young-Il Kim, et al.
Published: (2021-01-01)

Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial
by: Jorge Diaz, et al.
Published: (2025-06-01)

Persistence and decay of neutralizing antibody responses elicited by SARS-CoV-2 infection and hybrid immunity in a Canadian cohort
by: Amy Nouanesengsy, et al.
Published: (2025-04-01)

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
by: Danielle E. Anderson, et al.
Published: (2020-01-01)

Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response
by: Ali Toloue Ostadgavahi, et al.
Published: (2021-05-01)

Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk
by: Mallory C. Shriver, et al.
Published: (2025-05-01)

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
by: Jianhui Nie, et al.
Published: (2020-01-01)

Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection
by: Young Hoon Hwang, et al.
Published: (2025-12-01)

Factors Associated with Impaired Humoral Immune Response to mRNA Vaccines in Patients with Inflammatory Bowel Disease: A Matched-Cohort Analysis from the RisCoin Study
by: Katarina Csollarova, et al.
Published: (2025-06-01)

Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody
by: Christopher W. Farnsworth, et al.
Published: (2025-04-01)

Mechanism of modified mRNA structure in COVID-19 vaccines for inducing neutralizing antibodies
by: Sabighoh Zanjabila, et al.
Published: (2024-10-01)

Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants
by: Léa Dépéry, et al.
Published: (2025-01-01)

An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants
by: Lineth Juliana Vega Rojas, et al.
Published: (2024-12-01)

Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
by: Belén Aparicio, et al.
Published: (2021-01-01)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024-12-01)

SARS-CoV-2 spike S2-specific neutralizing antibodies
by: Chia-Jung Li, et al.
Published: (2023-12-01)

«DELTA-VAC» SUBUNIT VACCINE INDUCES STRONG HUMORAL IMMUNE RESPONSE AGAINST SARS-COV-2
by: Valentina Sergeevna Nesmeyanova, et al.
Published: (2019-08-01)

Humoral response against COVID-19 in the population of western region of Poland
by: Dominika Siedlecka, et al.
Published: (2025-08-01)

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses
by: Rui Qiao, et al.
Published: (2025-05-01)

High neutralizing antibody titer in intensive care unit patients with COVID-19
by: Li Liu, et al.
Published: (2020-01-01)

What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
by: Sanda Ravlić, et al.
Published: (2023-12-01)

Study on SARS-CoV-2 infection in middle-aged and elderly population infected with hepatitis virus: a cohort study in a rural area of northeast China
by: Yuchen Pan, et al.
Published: (2025-02-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection
by: Veronika Vaňová, et al.
Published: (2025-05-01)

Virus-specific humoral immune response in Bulgarian COVID-19 patients with varying disease severity
by: Evelina Shikova, et al.
Published: (2023-12-01)

SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1
by: Biao Zhou, et al.
Published: (2023-12-01)

Monitoring humoral responses against three SARS-CoV-2 vaccines in a university population from Chihuahua, Mexico
by: Inés V Chavarría-Bencomo, et al.
Published: (2024-09-01)

Humoral Immunity Profiling to Pandemic and Bat‐Derived Coronavirus Variants: A Geographical Comparison
by: Parinaz Fathi, et al.
Published: (2025-01-01)

T Cell Responses to SARS-CoV-2 in Vaccinated Pregnant Women: A Comparative Study of Pre-Pregnancy and During-Pregnancy Infections
by: Ching-Ju Shen, et al.
Published: (2024-10-01)

Delayed Viral Clearance Accompanied by Early Impaired Humoral and Virus-Specific T-Cell Response in Patients with Coronavirus Disease 2019 and Interstitial Lung Disease
by: Jiaying Zhong, et al.
Published: (2025-06-01)

Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up
by: Camila Amormino Corsini, et al.
Published: (2025-07-01)

Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies
by: Wenling Jiang, et al.
Published: (2024-12-01)

A high-throughput, fully automated competition assay to evaluate SARS-CoV-2 neutralizing responses and epitope specificity in clinical samples
by: Yusuke Atarashi, et al.
Published: (2025-04-01)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
by: Jialu Zhang, et al.
Published: (2021-01-01)

Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses
by: Beatriz L. L. Caetano, et al.
Published: (2025-08-01)